Citation Impact
Citing Papers
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
2015
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
2015
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Lung cancer statistics, 2023
2024
Breast cancer
2019 Standout
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
2015
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
2013
Breast-cancer detection using blood-based infrared molecular fingerprints
2021 StandoutNobel
Cancer statistics, 2024
2024 Standout
A view on drug resistance in cancer
2019 StandoutNature
Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
2013
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations
2016
Multiparametric Analysis of Cell-Free DNA in Melanoma Patients
2012
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
2016
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
2015
Lung cancer: current therapies and new targeted treatments
2016 Standout
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
2012
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
2015
Liquid biopsy
2015
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
2017
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
2017
Integrated digital error suppression for improved detection of circulating tumor DNA
2016
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
2016
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer
2016
Frequent detection of BRAFV 600E mutations in histiocytic and dendritic cell neoplasms
2014
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
2018
Works of Rose McCormack being referenced
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
2012
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
2016
Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer
2015
Circulating tumour-derived predictive biomarkers in oncology
2010
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
2011
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
2014
Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib
2009
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
2013
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
2015